Company / Cash & Equivalents
Bio Green Med Solution, Inc. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.5M
FY2025
5-year range
$3.5M / $24.2M
FY2021-FY2025
Trend
-85.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $4M in FY2025 to $31M in FY2013.
Based on SEC 10-K filings.
$4M in FY2025 with a 10-year CAGR of -16.2%.
Declined from $17M to $4M over the past 9 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -16.2%
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 85.3% year-over-year.
- Peak cash & equivalents was recorded in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -47.65 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -85.3% |
| FY2017 | $23.9M | +44.7% |
| FY2016 | $16.5M | -19.2% |
| FY2015 | $20.4M | -15.5% |
| FY2014 | $24.2M | -22.3% |
| FY2013 | $31.1M | +89.8% |
| FY2012 | $16.4M | -32.9% |
| FY2011 | $24.4M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026